Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  blinatumomab
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-5 of 5 for your search:
Start Over
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 35 to 70
Sponsor: NCI
Protocol IDs: NCI-2013-02229, ECOG-E1910, E1910, U10CA180820, U10CA021115, NCT02003222
Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 00103311, NCT02013167
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 17 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20120215, 2014-002476-92, NCT02393859
Study of Blinatumomab in Japanese Adults With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20130265, NCT02412306
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01047, SWOG-S1318, S1318, U10CA180888, NCT02143414
Start Over